Therapeutic options for advanced papillary, follicular, and anaplastic thyroid carcinomas are limited. Novel therapeutic strategies are currently under investigation in clinical studies. Among the therapeutic principles of these strategies are the inhibitions of proliferation and angiogenesis, as well as the induction of re-differentiation of malignant cells. Curative therapeutic strategies are not available to date. According to current data, kinase inhibitors which modulate cell proliferation and angiogenesis are the most promising drugs to prolong survival. Patients suffering from one of these three thyroid carcinomas should participate in clinical trials. In most cancer centers, sorafenib is the substance of first choice to treat patients not recruited for clinical trials. Sequential therapeutic steps with different drugs will play an important role in prolonging patient survival and improving quality of life.
|Translated title of the contribution||Non-medullary thyroid cancer - New strategies und current therapeutic options|
|Number of pages||4|
|Publication status||Published - 14.11.2012|